Status:
COMPLETED
Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia
Lead Sponsor:
Sangart
Conditions:
Vascular Disease
Critical Lower Limb Ischemia
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb isc...
Detailed Description
Hemospan® is a novel hemoglobin-based oxygen carrier developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. Because of its molecular size and oxygen binding characteristics, Hemos...
Eligibility Criteria
Inclusion
- Adult male or female (surgically sterile or post-menopausal) patients with CCLI that meet the following definition: i) History of pain at rest and/or ulceration; ii) Ankle systolic BP/Brachial systolic BP Index (ABI) \<0.6 at the time of inclusion; iii) Ankle systolic BP \<70 mmHg and/or toe systolic BP \<50 mmHg
- Has received written and verbal information about the investigational product and the protocol by the investigator and has had the opportunity to ask questions about the study
- Patients must sign an Informed Consent Form (ICF), that has been reviewed and approved by the independent Ethics Committee (EC)
Exclusion
- Severe congestive heart failure (EF \<40%, or New York Heart Association Class III or IV
- Any acute or chronic condition that will limit the patient's ability to complete the study
- Recent acute coronary syndrome (unstable angina or myocardial infarction \[MI\] within 1 month)
- Severe dementia or clinically significant psychiatric disorder requiring active treatment
- Evidence of untreated or uncontrolled hypertension (SBP \>180 mmHg, or DBP \>100 mmHg), or a difference in systolic BP in each arm that is \>15 mmHg (measured by cuff and a pen-Doppler at screening in the supine position, in both arms)
- Smoking or use of any nicotine-containing product (e.g., snuff) within previous 24 hours before start of study
- Any systemic rheumatic disease
- Taking oral steroid therapy (does not include steroids taken intermittently via inhaler)
- Chronic hepatic disease (abnormal LFTs \>3X upper limit of normal, known history of Hepatitis C or B)
- Chronic renal disease (creatinine \>1.8 mg/dL, or known polycystic kidney disease)
- Expectation of poor patient compliance with study protocol
- Patients scheduled for surgical procedure within 7 days from start of this study
- Involved in any investigational drug or device trial within 30 days prior to this study
- Professional or ancillary personnel involved with this study
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00633659
Start Date
September 1 2007
End Date
December 1 2008
Last Update
August 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Universitetssjukhuset
Stockholm, Sweden